CIHI: On December 17, the Canadian Institute for Health Information (CIHI) published statistics1 on drug spending, finding that in 2018, around 40% of drug spending was spent on 2% of beneficiaries. Out of this 2%, three out of five individuals used a drug therapy that cost $10,000 or more per year (e.g. antivirals or biologics for rheumatoid arthritis/Crohn’s disease). The top increases in drug spending over the past 5 years were for drug classes with average annual costs of $10,000 or more.
PMPRB Meds Entry Watch: In January 2020, the PMPRB released the Meds Entry Watch 2018, which analyzes information about medicines approved by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and/or Health Canada in 2017 and 2018.
Consistent with the CIHI report, one of the key findings is the continued upward trend in the entry of high-cost products (such as orphan drugs and oncology products), with nearly two thirds of the medicines approved internationally in 2017 having treatment costs over $10,000 per year, or $5,000 per 28-day cycle for oncology medicines.
References
1. Link to the original source is no longer available. See the 2019 report for more details.
Related Publications & Articles
-
PMPRB news: Upcoming roundtable as first phase of new guidelines consultation, two new appointments
On October 25, 2023, the Patented Medicine Prices Review Board (PMPRB) announced that it will launch the first phase of consultations on new guidelines.Read More -
PMPRB publishes scoping paper for consultation on guidelines and invites stakeholder feedback
The Patented Medicine Prices Review Board announced that it will launch the first phase of consultations on new guidelines. On November 10, 2023, the PMPRB published its Scoping Paper for the Consulta...Read More -
Ontario Ministry of Health proposes regulatory amendments removing submission requirements for well-established drugs
On October 19, 2023, the Ontario Ministry of Health proposed regulatory amendments under the Ontario Drug Benefit Act (ODBA) and the Drug Interchangeability and Dispensing Fee Act (DIDFA) to align Ont...Read More